Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RRBP1 promotes osimertinib resistance by activating fatty acid oxidation-dependent metabolic and immune reprogramming in EGFR-Mutant lung adenocarcinoma.

Biochemical pharmacology - 1 Sept 2026

Huang Yajie, Zhang Yaozhong

Abstract excerpt

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that improves clinical outcomes in patients with EGFR-mutant lung adenocarcinoma (LUAD); however, acquired resistance remains a major limitation. Increasing evidence suggests that metabolic reprogramming within the tumor microenvironment contributes to drug resistance, whereas the molecular mechanisms linking lipid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Fatty Acids

Share to Indoles

Share to Oxidation-Reduction

Share to Pyrimidines

Share to Sterol Regulatory Element Binding Protein 1

Source

Identifiers

PMID: 42285369
DOI: 10.1016/j.bcp.2026.118158

Genes

RRBP1
EGFR
CPT1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RRBP1 promotes osimertinib resistance by activating fatty acid oxidation-dependent metabolic and immune reprogramming in EGFR-Mutant lung adenocarcinoma.PMID 42285369Read ↗

Integrating Single-Cell RNA-Seq and Bulk RNA-Seq to Explore the Key Role of Fatty Acid Metabolism in Breast CancerSemantic proximity Read ↗

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity Read ↗

A lenvatinib-resistance-derived transcriptional program identifies metabolic identity remodeling associated with unfavorable survival in hepatocellular carcinomaSemantic proximity Read ↗

Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy.Semantic proximity Read ↗

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceSemantic proximity Read ↗

Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancerSemantic proximity Read ↗

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic VulnerabilitiesSemantic proximity Read ↗

EGFR Mutation Subtypes Modulate Distinct Metabolic Profiles and Clinical Outcomes in Lung Cancer: A Retrospective AnalysisSemantic proximity Read ↗

Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor AlphaSemantic proximity Read ↗

FAM155B driven by BPTF promotes breast cancer progression and paclitaxel resistance via SREBP1-mediated fatty acid metabolic reprogrammingSemantic proximity Read ↗

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read ↗

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.